Harrow Health, Inc. (HROW)
- Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
NASHVILLE, Tenn., June 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medi
- InvestorPlace
7 Mighty Micro-Cap Stocks That Could Be Future Moonshots
Source: iQoncept / Shutterstock.com Given the way the market’s acting today, now may not seem like the best time to pursue “moonshot” plays. Rising interest rates keep putting pressure on formerly high-flying growth stocks. Meme stocks are struggling to hold onto what’s left of their “to the moon” gains. Yet for investors, there’s an area that may provide such high-risk, high-potential opportunities: micro-cap stocks. Micro-caps, or stocks with market capitalizations under $300 million, are an u
- Simply Wall St.
Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders?
Every investor in Harrow Health, Inc. ( NASDAQ:HROW ) should be aware of the most powerful shareholder groups...
